Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Edan Instruments, Inc. (300206.SZ)
Shenzhen, CN
Edan Instruments, Inc. is a global provider specializing in the development, manufacturing, and worldwide distribution of a comprehensive range of medical equipment. Their diagnostic electrocardiograph (ECG) portfolio covers a variety of solutions, such as resting ECG, stress testing, Holter monitoring, wireless options, and dedicated ECG workstations. For patient monitoring, Edan offers systems addressing vital signs, transport, central monitoring, and various levels of care—from high acuity to acute and sub-acute settings—along with telemetry and pulse oximetry devices. In the field of obstetrics and gynecology, their offerings include fetal and maternal monitoring systems, fetal telemetry, ultrasonic Doppler devices, and video colposcopes. The company's ultrasound imaging systems encompass both color Doppler and black-and-white digital units. Additionally, Edan provides in-vitro diagnostics (IVD) like hematology analyzers, and a suite of point-of-care testing (POCT) systems, including analyzers for blood gas and chemistry, magnetic immunoassay, and colloidal gold-labeled immunoassay. They also cater to the veterinary market with specialized ultrasound, ECG, ABG, and monitoring products. Edan Instruments, Inc. maintains its headquarters in Shenzhen, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+9.0% Q1'26: +22.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+89.3% ★ Q1'26: +63.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+14.0% Q1'26: -1.8% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+15.9% ★ Q1'26: +21.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+33.4% ★ Q1'26: +39.3% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.05× ★ Q1'26: 0.06× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
550.14M
est: 664.00M (-17.1%)
|
698.01M
est: 819.00M (-14.8%)
|
843.28M
est: 892.00M (-5.5%)
|
992.72M
est: 1.04B (-4.4%)
|
1.14B
est: 1.14B (0.0%)
|
2.32B
est: 2.27B (+2.2%)
|
1.64B
est: 2.46B (-33.5%)
|
1.99B
est.
|
1.74B
est: 1.98B (-12.0%)
|
1.94B
est: 1.98B (-2.1%)
|
1.83B
est: 1.88B (-2.3%)
|
2.00B
est: 2.02B (-1.0%)
|
2.23B
2.23B – 2.23B
+10.2% YoY
|
2.45B
2.45B – 2.45B
+10.2% YoY
|
| EBITDA |
124.32M
est: 128.39M (-3.2%)
|
51.39M
est: 158.36M (-67.5%)
|
74.00M
est: 172.47M (-57.1%)
|
127.51M
est: 200.70M (-36.5%)
|
166.80M
est: 219.77M (-24.1%)
|
794.16M
est: 438.71M (+81.0%)
|
294.73M
est: 475.73M (-38.0%)
|
385.35M
est.
|
294.28M
est: 382.84M (-23.1%)
|
269.48M
est: 382.84M (-29.6%)
|
213.65M
est: 297.01M (-28.1%)
|
372.27M
est: 319.47M (+16.5%)
|
352.05M
352.05M – 352.05M
+10.2% YoY
|
388.11M
388.11M – 388.11M
+10.2% YoY
|
| EBIT |
105.04M
est: 109.41M (-4.0%)
|
21.90M
est: 134.95M (-83.8%)
|
38.36M
est: 146.98M (-73.9%)
|
89.75M
est: 171.03M (-47.5%)
|
127.79M
est: 187.29M (-31.8%)
|
750.99M
est: 373.86M (+100.9%)
|
249.77M
est: 405.41M (-38.4%)
|
328.39M
est.
|
245.42M
est: 326.25M (-24.8%)
|
223.47M
est: 326.25M (-31.5%)
|
168.20M
est: 247.66M (-32.1%)
|
317.60M
est: 266.39M (+19.2%)
|
293.55M
293.55M – 293.55M
+10.2% YoY
|
323.62M
323.62M – 323.62M
+10.2% YoY
|
| Net Income |
103.21M
est: 39.41M (+161.9%)
|
26.35M
est: 55.64M (-52.6%)
|
43.77M
est: 81.14M (-46.1%)
|
92.65M
est: 63.75M (+45.3%)
|
131.85M
est: 133.30M (-1.1%)
|
653.15M
est: 707.09M (-7.6%)
|
231.44M
est: 591.17M (-60.9%)
|
347.75M
est.
|
232.94M
est: 266.61M (-12.6%)
|
221.30M
est: 266.61M (-17.0%)
|
162.11M
est: 197.18M (-17.8%)
|
305.64M
est: 202.98M (+50.6%)
|
255.17M
255.17M – 255.17M
+25.7% YoY
|
301.57M
301.57M – 301.57M
+18.2% YoY
|
| SGA |
330.56M
est: 133.43M (+147.7%)
|
388.81M
est: 164.58M (+136.2%)
|
270.13M
est: 179.25M (+50.7%)
|
319.96M
est: 208.59M (+53.4%)
|
344.54M
est: 228.41M (+50.8%)
|
405.29M
est: 455.95M (-11.1%)
|
427.32M
est: 494.43M (-13.6%)
|
400.50M
est.
|
492.95M
est: 397.89M (+23.9%)
|
589.93M
est: 397.89M (+48.3%)
|
574.80M
est: 471.47M (+21.9%)
|
186.78M
est: 507.12M (-63.2%)
|
558.83M
558.83M – 558.83M
+10.2% YoY
|
616.07M
616.07M – 616.07M
+10.2% YoY
|
| EPS |
0.18
est: 0.07 (+164.7%)
|
0.05
est: 0.10 (-53.1%)
|
0.07
est: 0.14 (-46.6%)
|
0.16
est: 0.11 (+45.5%)
|
0.23
est: 0.23 (+0.0%)
|
1.12
est: 1.22 (-8.2%)
|
0.40
est: 1.02 (-60.8%)
|
0.60
est.
|
0.40
est: 0.46 (-13.0%)
|
0.38
est: 0.46 (-17.4%)
|
0.28
est: 0.34 (-17.6%)
|
0.53
est: 0.35 (+51.4%)
|
0.44
0.44 – 0.44
+25.7% YoY
|
0.52
0.52 – 0.52
+18.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.76% | 533.6K | 0.95% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 93.0K | 0.65% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 284.4K | 0.06% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 164.5K | 0.39% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 108.4K | 0.29% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 95.5K | 0.28% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 20.0K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.9K | 0.48% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 989.3K | 0.06% |
| 10 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 3.6K | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hao Zhang | Chairman & President | — | male |
| Xicheng Xie | Vice President & Non-Independent Director | — | male |
| Youdong Zu | Chief Financial Officer, Vice President, Secretary, Director & Accounting Supervisor | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300206.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
